Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections. Supplementary data

<strong>Supplementary Table 1</strong><em><strong>. </strong></em><em>Reduced odds for a severe infection in the follow up (post-index) period, with IgPro10, adjusting for covariates: A general linear model in matched cohorts* restricted to patients with at least 6 months of follow up.</em>
<br>
<em>Supplementary material 2: International Classification of Diseases, Ninth and Tenth Revision (ICD-9/10), Current Procedural Terminology (CPT), Healthcare Common Procedure Coding System (HCPCS) and RxNorm codes used for inclusion/exclusion in the study.</em>